Operator

I'm on the Bank of America Life Science Tools and Diagnostics team. And for our next chat, we're excited to host Guardant Health. We're joined by Co-Chief Executive Officer, Helmy Eltoukhy; and Mike Bell, Chief Financial Officer.

Helmy, Mike, thank you so much for being here. Really appreciate you taking the time. Yes. Great to be here.

Unknown Analyst

[Operator Instructions]

Maybe we'll start with a high-level question. You guys just reported first quarter just a couple of days ago, really strong broad-based nice raise.

Talk through how the quarter played out to your expectations and where things came a little bit better and how you're thinking that going forward?

Helmy Eltoukhy
Co-Founder, Co-CEO & Chairman

Yes. I mean I think it's been exciting to see us sort of lean into the [indiscernible] that we're embarking on in terms of utilization adoption [indiscernible] doing really well and that I think the smart platform is a gift that keeps on giving and [indiscernible]. There's a thing in diagnostic therapeutics, how you start having strong first quarter [indiscernible] MRD.

I think it does [indiscernible] obviously are pushing longitudinal testing, pushing in the indications we're in and had a very strong start [indiscernible] And we're very excited about where that is going up to [indiscernible] impressive given, [indiscernible] [Technical Difficulty]

Unknown Analyst

Maybe we'll just build on that in terms of taking that into the full year guide raise. You raised the guide by more than you beat. You updated some of your assumptions for oncology for Shield. Sort of what gives you confidence in that momentum continuing?